While Acadia Pharmaceuticals Inc has underperformed by -3.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACAD fell by -26.64%, with highs and lows ranging from $32.59 to $14.15, whereas the simple moving average fell by -2.86% in the last 200 days.
On October 10, 2024, Raymond James started tracking Acadia Pharmaceuticals Inc (NASDAQ: ACAD) recommending Mkt Perform. A report published by Morgan Stanley on August 07, 2024, Downgraded its rating to ‘Equal-Weight’ for ACAD. BMO Capital Markets also rated ACAD shares as ‘Outperform’, setting a target price of $31 on the company’s shares in an initiating report dated June 27, 2024. Needham Reiterated the rating as Buy on March 12, 2024, but set its price target from $36 to $32. Mizuho March 12, 2024d its ‘Buy’ rating to ‘Neutral’ for ACAD, as published in its report on March 12, 2024. Robert W. Baird’s report from January 30, 2024 suggests a price prediction of $40 for ACAD shares, giving the stock a ‘Outperform’ rating. Needham also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Acadia Pharmaceuticals Inc (ACAD)
Further, the quarter-over-quarter increase in sales is 18.28%, showing a positive trend in the upcoming months.
One of the most important indicators of Acadia Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 27.36% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.11, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ACAD is recording 1.34M average volume. On a monthly basis, the volatility of the stock is set at 3.71%, whereas on a weekly basis, it is put at 4.07%, with a loss of -1.05% over the past seven days. Furthermore, long-term investors anticipate a median target price of $25.00, showing growth from the present price of $17.02, which can serve as yet another indication of whether ACAD is worth investing in or should be passed over.
How Do You Analyze Acadia Pharmaceuticals Inc Shares?
The Biotechnology market is dominated by Acadia Pharmaceuticals Inc (ACAD) based in the USA. When comparing Acadia Pharmaceuticals Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 22.03, there is a growth in quarterly earnings of 149.70%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.76%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 96.20% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ACAD shares are owned by institutional investors to the tune of 96.20% at present.
